SCHEMBL6071835

SCHEMBL6071835

COc1cc2c(c3c1OC(C)(C)C3)C(c1cccc(NC(=O)CCC(=O)O)c1)=NC(C)(C)C2

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FFAR4 Q5NUL3 4/20 0.38
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GFER P55789 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
POLB P06746 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072373 0.94 LMNA (0.38) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL5785872 0.93 IDO1 (0.39) MEN1KMT2AFFAR4LMNAPOLB
SCHEMBL6072198 0.93 LMNA (0.37) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL6072102 0.93 LMNA (0.38) MEN1KMT2AFFAR4LMNAALDH1A1
SCHEMBL5784678 0.92 LMNA (0.37) MEN1KMT2AFFAR4LMNAALDH1A1
SCHEMBL5786842 0.91 LMNA (0.38) KMT2ALMNAALDH1A1MAPTTSHR
SCHEMBL5784815 0.91 LMNA (0.36) MEN1KMT2AFFAR4LMNAALDH1A1
SCHEMBL5786230 0.90 LMNA (0.38) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL6071836 0.90 POLB (0.38) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL5785643 0.89 LMNA (0.35) MEN1KMT2AFFAR4LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A MEN1 1942/4885KMT2A 878/4885FFAR4 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.